Mustang Bio, Inc.

Healthcare · Biotechnology · United States

Last price 0.4001 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 3.03M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Rα2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an ...